Ondansetron Aurobindo

Ondansetron, the active ingredient in Ondansetron Aurobindo, is a 5‑HT3 receptor antagonist presented as an oral formulation for oral use. It helps prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery.

GNH USA supplies Ondansetron Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting.

Chemotherapy-induced nausea and vomiting: prevents and treats nausea and vomiting in patients receiving cytotoxic chemotherapy. Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. Radiation-induced nausea and vomiting: helps control nausea and vomiting caused by radiotherapy.

Common Side Effects: - Headache: mild to moderate pain often reported during treatment. - Constipation: reduced bowel movements may occur. - Dizziness: transient sensation of light‑headedness. - Fatigue: feelings of tiredness or lack of energy. - Diarrhoea: loose stools in some patients.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare but serious condition when combined with other serotonergic drugs. - Cardiac arrhythmias: irregular heartbeats beyond QT prolongation. - Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, consider the following precautions.

Assess cardiac risk: evaluate baseline ECG and QT interval. Avoid concomitant QT‑prolonging agents: limit use with other drugs that affect cardiac repolarisation. Use caution in hepatic impairment: dose may need adjustment in patients with liver dysfunction. Monitor electrolytes: correct hypokalaemia and hypomagnesaemia to reduce cardiac risk. Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Ondansetron may interact with several medication classes.

Major Interactions (Avoid): - Other QT‑prolonging drugs: additive risk of serious arrhythmias. - Cisapride: contraindicated due to synergistic QT effects. - Serotonergic agents (e.g., tramadol, linezolid): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise ondansetron plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness. - Anticholinergic agents: may diminish ondansetron's anti‑emetic efficacy.